In a report published by Piper Jaffray, Sequenom SQNM reported revenue and LPS above its, and Street, consensus expectations.
Piper Jaffray said that Sequenom generally remains on-track for the T21 assay LDT launch by the end of the year (or early 2012). “We are encouraged with the reiteration of development/commercialization time-lines. We maintain our Overweight rating and $8.50 price target on SQNM shares.”
Sequenom closed yesterday at $5.82.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareLife Sciences Tools & ServicesPiper JaffraySequenom
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in